





**A)****B)****C)****D)**

**Figure 5. A-bomb survivor leukemia risks.** **A)** High dose AML risks (blue;  $>1$  Sv) paralleling controls (gray;  $<0.02$  Sv), ignoring the first age group, supports relative AML risks. High dose CML risk flatness supports additive CML risks. **B)** CML low dose risks (yellow;  $0.02$ - $1$  Sv) are higher than control risks (gray), consistent with steep risks in D. **C)** High dose risks remain high for AML and ALL, but not CML. **D)** Risks across low doses ( $<1$  Sv) are consistent with dose-response shapes being purely quadratic for AML, linear-to-sublinear for ALL, and linear for CML.